De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Joinn Laboratories(China)Co.Ltd Toekomstige groei

Future criteriumcontroles 3/6

Joinn Laboratories(China)Co.Ltd zal naar verwachting groeien in winst en omzet met respectievelijk 63.6% en 11.1% per jaar. De winst per aandeel zal naar verwachting groeien met 63.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 5.4% zijn.

Belangrijke informatie

63.8%

Groei van de winst

63.6%

Groei van de winst per aandeel

Life Sciences winstgroei	29.1%
Inkomstengroei	10.8%
Toekomstig rendement op eigen vermogen	5.3%
Dekking van analisten	Good
Laatst bijgewerkt	08 Oct 2024

Recente toekomstige groei-updates

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03

Recent updates

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Oct 01

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Jul 28

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Apr 04

Winst- en omzetgroeiprognoses

SHSE:603127 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2,861	544	498	899	8
12/31/2025	2,462	417	793	777	10
12/31/2024	2,189	75	16	343	8
6/30/2024	2,214	137	316	534	N/A
3/31/2024	2,332	-63	561	756	N/A
12/31/2023	2,376	397	430	623	N/A
9/30/2023	2,579	770	435	641	N/A
6/30/2023	2,503	794	410	672	N/A
3/31/2023	2,366	1,137	624	882	N/A
12/31/2022	2,268	1,074	696	971	N/A
9/30/2022	1,936	941	680	1,000	N/A
6/30/2022	1,759	775	754	1,029	N/A
3/31/2022	1,587	589	462	726	N/A
12/31/2021	1,517	557	448	686	N/A
9/30/2021	1,301	419	506	668	N/A
6/30/2021	1,213	379	319	477	N/A
3/31/2021	1,122	389	261	429	N/A
12/31/2020	1,076	315	279	428	N/A
9/30/2020	922	253	129	275	N/A
6/30/2020	836	237	95	229	N/A
3/31/2020	720	194	38	166	N/A
12/31/2019	639	187	21	148	N/A
9/30/2019	513	128	-1	152	N/A
6/30/2019	475	126	52	192	N/A
3/31/2019	432	112	59	185	N/A
12/31/2018	409	108	46	176	N/A
9/30/2018	375	99	85	176	N/A
6/30/2018	341	87	75	145	N/A
3/31/2018	334	92	N/A	136	N/A
12/31/2017	301	76	N/A	123	N/A
9/30/2017	294	74	N/A	140	N/A
12/31/2016	242	52	N/A	119	N/A
12/31/2015	207	49	N/A	106	N/A
12/31/2014	185	49	N/A	82	N/A
12/31/2013	144	22	N/A	61	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 603127 ( 63.6% per jaar) ligt boven de spaarquote ( 2.9% ).

Winst versus markt: De winst van 603127 ( 63.6% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 23.2% per jaar).

Hoge groeiwinsten: De winst van 603127 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 603127 ( 11.1% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.2% per jaar).

Hoge groei-inkomsten: De omzet van 603127 ( 11.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 603127 zal naar verwachting over 3 jaar laag zijn ( 5.4 %).

Joinn Laboratories(China)Co.Ltd Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 27%

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Consensus revenue estimates fall by 19%

Consensus EPS estimates fall by 19%

Price target decreased by 8.6% to CN¥22.33

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Recent updates

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Joinn Laboratories(China)Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Consensus EPS estimates fall by 27%

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Dividend of CN¥0.16 announced

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Consensus revenue estimates fall by 19%

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates fall by 19%

Price target decreased by 8.6% to CN¥22.33

Investor sentiment improves as stock rises 19%

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Now 23% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Price target decreased by 7.2% to CN¥25.92

Price target decreased by 7.3% to CN¥28.66

Now 20% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Consensus EPS estimates fall by 27%

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 700%

New minor risk - Share price stability

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 10%

Price target decreased by 11% to CN¥33.30

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to CN¥37.55

Now 25% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased by 8.7% to CN¥57.93

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥8.9m worth of stock

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 09, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.4% to CN¥70.19

Price target increased by 7.4% to CN¥76.57

Insider recently sold CN¥56m worth of stock

JOINN Laboratories (China) Co., Ltd. Provides Revenue Guidance for the Period January 1, 2022 to December 31, 2022

Insider recently sold CN¥57m worth of stock

Co-Founder & Vice Chairman recently sold CN¥31m worth of stock

Insider recently sold CN¥30m worth of stock

Co-Founder & Vice Chairman recently sold CN¥65m worth of stock

Price target decreased to CN¥71.30

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Co-Founder & Vice Chairman recently sold CN¥180m worth of stock

Price target increased to CN¥86.02

Insider recently sold CN¥60m worth of stock

Now 21% undervalued after recent price drop

Price target decreased to CN¥74.80

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.11 in 2Q 2021)

Joinn Laboratories(China)Co.,Ltd. SHS (China) to Be Deleted from OTC Equity